CDSCO Panel Gives Conditional nod to Azelnidipine and Olmesartan FDC MD Bureau18 Jan 2021 1:21 PM GMTNew Delhi: Following the submission of bioequivalence (BE) study report by Akum Drugs, the Central Drug Standard Control...
Avoiding Aldosterone Breakthrough in Hypertensive Diabetics: Role of Azelnidipine Dr. Prem Aggarwal28 Dec 2020 7:00 AM GMTAzelnidipine may contribute to avoid the 'aldosterone breakthrough' by its suppressive effects on aldosterone synthesis and secretion
Impact of Azelnidipine in reducing urinary albumin excretion and carotid atherosclerosis in type 2 diabetes patients: BOAT 2 study Review Dr. Prem Aggarwal15 Dec 2020 7:15 AM GMTHypertension and Diabetes Mellitus are the global health burden and strong risk factors for coronary artery disease (1). Impaired glucose tolerance...
Azelnidipine versus Amlodipine in hypertensive diabetics with albuminuria: Review Dr. Prem Aggarwal27 Nov 2020 7:15 AM GMTHypertension is common among diabetics and those who have chronic kidney disease. Both hypertension and diabetes are associated with increased...
Role of Azelnidipine on management of BP in hypertensive Diabetics: Review Dr. Prem Aggarwal4 Nov 2020 5:39 AM GMTHypertensive patients with type 2 diabetes carry a high cardiovascular risk. Most patients with hypertension and diabetes face higher mortality due to ...
Effective BP control: High dose ARB monotherapy or combination therapy of ARB and CCB for hypertension? Dr. Prem Aggarwal10 Oct 2020 5:00 AM GMTHypertension (HTN) is a global health hazard and a leading cause of mortality and morbidity. It is ranked third as a cause for disability-adjusted...
Effects of Azelnidipine versus Amlodipine on LV Mass and Longitudinal Function in Hypertensive Patients with LVH Dr. Prem Aggarwal19 Sep 2020 5:30 AM GMTLeft ventricular hypertrophy (LVH) is the structural remodelling of the heart which is a serious consequence of systemic hypertension. It is a...
Impact of Azelnidipine treatment on left ventricular diastolic performance in patients with BP and mild diastolic dysfunction: CALVLOC trial Dr. Prem Aggarwal28 Aug 2020 7:00 AM GMTOne of the most common forms of heart failure is Left Ventricular Diastolic Dysfunction. Patients with hypertension are at particular risk of heart...
Controlling Variability in Home Blood Pressure: Which Combination therapy is better? Dr. Prem Aggarwal11 Aug 2020 7:23 AM GMTHypertension is one of the most preventable causes of death worldwide that accounts for more than 12.8% of all deaths annually. Elevated blood...
Impact of Combination Therapy on Arterial Stiffness and Cardiac Function in hypertensive patients: Lessons from AORTA II Trial Dr. Prem Aggarwal28 July 2020 7:00 AM GMTManagement of Blood pressure (BP) in patients is a highly individualized affair. When adequate blood pressure control is not be obtained by...
Combination therapy for Hypertension: Olmesartan plus Azelnidipine or Olmesartan plus Amlodipine? Dr. Prem Aggarwal14 July 2020 7:15 AM GMTThe Protocol of Controlling Blood pressure (BP) in Hypertensive Patients is different in different parts of the world. Achieving adequate blood...
Ameliorating Glucose Intolerance with BP Control: Azelnidipine or Amlodipine? Dr. Prem Aggarwal2 July 2020 7:15 AM GMTStudy demonstrated that azelnidipine administration rather than amlodipine administration significantly ameliorated glucose intolerance and the...
